Navigation Links
Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
Date:6/30/2008

Company's End-of-Phase II Meeting with FDA Set for Sept. 29

LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that data presented at the 50th Annual Scientific Meeting of the American Headache Society showed that, in addition to meeting the primary endpoint of headache pain relief at two hours, the company's lead AMPA/kainate-type glutamate receptor antagonist, tezampanel, demonstrated improvement on important secondary endpoints in a 306-patient Phase IIb clinical trial in acute migraine headache. Specifically, tezampanel demonstrated improvement in the following secondary endpoints: sustained headache response, absence of nausea or vomiting, absence of phonophobia and absence of photophobia.

"This is our second positive study in acute migraine with tezampanel," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics, who presented the data. "In both studies, we have shown improvement in all of the endpoints that the FDA has indicated will be required for the drug's approval. Earlier this year we conducted a clinical guidance call with the FDA in which the agency said it has no objection with us moving forward with a Phase III study of the 40 mg dose of tezampanel. We have scheduled an end-of-Phase II meeting to discuss the entire Phase III program with the agency on Sept. 29."

In the Phase IIb clinical trial, tezampanel was well tolerated with no reports of serious or medically important adverse events. At the 40 mg dose, the most commonly reported adverse events compared to placebo were injection site pain (5.1 percent vs. 20 percent), injection site burning (3.8 percent vs. 6.7 percent), dizziness (6.4 percent vs. 5.3 percen
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
3. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
4. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
7. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
8. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
9. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
10. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
11. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... CINCINNATI , May 21, 2013  Tom Daulton, CEO ... named Dealmaker of the Year by the Cincinnati ... Daulton, who was nominated by another local top executive who ... the Mammotome® brand from Ethicon Endo-Surgery in March of 2010. ... Deal Maker Awards program, presented by Huntington Bank, on May ...
(Date:5/21/2013)... PHILADELPHIA , May 21, 2013 ... and impressive new product developments at the Special Libraries Association ... years of unerring focus on product literature databases and workflow ... mark the occasion," said founding director Nigel Johnson ... developments of benefit to our clients and what better forum ...
(Date:5/21/2013)... -- Zacks.com announces the list of stocks featured in the ... discuss the latest news and events impacting stocks and ... include Actavis, Inc.,s (NYSE: ACT ), BP plc ... ), Petrobras (NYSE: PBR ) and Devon Energy ... http://photos.prnewswire.com/prnh/20101027/ZIRLOGO ) Get the most recent ...
Breaking Medicine Technology:Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 2Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 3Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 2The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 3The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 4The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 5
(Date:5/21/2013)... 21, 2013 Daily Gossip Magazine published well-documented ... readers and keep people informed on the latest weight loss ... have prepared an in-depth review of Kyle Leon’s ... for readers who want to lose weight or stay in ... Gossip the program was created by a popular fitness trainer, ...
(Date:5/21/2013)... GA (PRWEB) May 21, 2013 Patients of ... Care who have lost teeth due to gum disease and ... surgery for gum disease treatment with laser gum surgery. ... which have the highest success rate out of all tooth ... (LANAP) is a relatively new procedure cleared by the Food ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national law ... defective medical devices, is offering remarks on the closing argument ... of Fred E. Taylor v. Intuitive Surgical, 09-2-03136-5, Superior Court, ... 2013, Bloomberg report noted that the plaintiff’s attorney, ... dealership” in how it deployed its strategy to train doctors ...
(Date:5/21/2013)... 2013) Prostaglandin analogues (PGAs), drugs which lower intraocular ... people with glaucoma, but their use is not without ... dryness, changes in eye color and other side effects. ... also cause upper and lower eyelid drooping and other ... described in PLOS ONE . , Researchers from ...
(Date:5/21/2013)... New York, New York (PRWEB) May 21, 2013 ... dedicated to protecting the rights of victims injured by ... the Journal of Bone & Joint Surgery on May ... (MRI) can be used to identify complications that occur ... have any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
Breaking Medicine News(10 mins):Health News:Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine 2Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Glaucoma drug can cause droopy eyelids 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3
... ... is a collaborative effort by the National Association of Certified Professional ... (CfM), International Center for Traditional Childbearing (ICTC), North American Registry of ... celebrate a recent the efforts of The MAMA Campaign to secure ...
... , NEW YORK, Dec. 4 Care Investment Trust Inc. ... announced that its Board of Directors has declared a dividend of ... on December 22, 2009 to common shareholders of record on December ... , Care Investment Trust Inc. is a real estate investment ...
... , PEMBROKE, Bermuda, Dec. ... ) today announced that Scott Carmilani,President and Chief Executive Officer, and ... presenting at the 2009,Goldman Sachs U.S. Financial Services Conference being held ... December 8, 2009. , About Allied World ...
... , KANSAS CITY, Mo., Dec. 4 The large, two-day ... (NAFC) in Kansas City on Wednesday and Thursday is not just ... has not seen a doctor recently. All participants in the health ... attended the three previous large free clinic events this fall in ...
... , WASHINGTON, Dec. 4 ... control health care costs, Leapfrog,s purchaser members point to ... best quality care in the nation while attaining the ... three rural hospitals have been named 2009 Leapfrog Top ...
... study shows that muscle cells grown in the lab can ... performed in dogs and rats, might ultimately help treat patients ... This technique may be used to strengthen sphincters, which are ... your intestinal tract. Weakness in these areas can cause gastrointestinal ...
Cached Medicine News:Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: